Abstract
A new human breast cancer cell line, KPL-4, was recently isolated from the malignant pleural effusion of a breast cancer patient with an inflammatory skin metastasis. This cell line can be cultured under serum-free conditions and is tumorigenic in female athymic nude mice. Flow cytometric analysis revealed the expression of Erb B-1, -2 and -3. Dot blot hybridization showed a 15-fold amplification of the erb B-2. Reverse transcription-polymerase chain reaction analysis showed a detectable level of mRNA expression of all the Erb B family receptors. In addition, all the receptors were autophosphorylated under a serum-supplemented condition. Unexpectedly, transplanted KPL-4 tumours induced cachexia of recipient mice. A high concentration of interleukin-6 (IL-6) was detected in both the culture medium and the serum of mice. The weight of tumours significantly correlated with the serum IL-6 level. The antiproliferative effect of a humanized anti-Erb B-2 monoclonal antibody, rhuMAbHER2, was investigated. This antibody significantly inhibited the growth of KPL-4 cells in vitro but modestly in vivo. Loss of mouse body weight was partly reversed by rhuMAbHER2. These findings suggest that KPL-4 cells may be useful in the development of new strategies against breast cancer overexpressing the Erb B family receptors and against IL-6-induced cachexia.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Alimandi, M., Wang, L-M, Bottaro, D., Lee, C-C, Kuo, A., Frankel, M., Fedi, P., Tang, C., Lippman, M. & Pierce, J. H. (1997). Epidermal growth factor and betacellulin mediate signal transduction through coexpressed Erb B2 and Erb B3 receptors. EMBO J, 16, 5608–5617.
Band, V., Zajchowski, D., Stenman, G., Morton, C. C., Kulesa, V., Connolly, J. & Sager, R. (1989). A newly established metastatic breast tumor cell line with integrated amplified copies of ERB B2 and double minute chromosomes. Genes Chromosomes Cancer, 1, 48–58.
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., Rosen, P. P., Twaddell, T., Henderson, I. C. & Norton, L. (1996). Phase II study of weekly intravenous recombinant humanized anti-p185HER2monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. J Clin Oncol, 14, 737–744.
Baselga, J., Norton, L., Albanell, J., Kim, Y-M & Mendelsohn, J. (1998). Recombinant humanized anti-HER2 antibody (HerceptinTM) enhances the antitumour activity of paclitaxel and doxorubicin against HER2/neu overexpressiong human breast cancer xenografts. Cancer Res, 58, 2825–2831.
Beerli, R. R., Graus-Porta, D., Woods-Cook, K., Chen, X., Yarden, Y. & Hynes, N. E. (1995). Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol Cell Biol, 15, 6496–6505.
Carraway, K. L. & Cantley, L. C. (1994). A neu acquaintance for ErbB3 and ErbB4: a role for receptor heterodimerization in growth signaling. Cell, 78, 5–8.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E. & Shepard, H. M. (1992). Humanization of an anti-p185HER2antibody for human cancer therapy. Proc Natl Acad Sci USA, 89, 4285–4289.
Charpin, C., Bonnier, P., Khouzami, A., Vacheret, H., Andrac, L., Lavaut, M. N., Allasta, C. & Piana, L. (1992). Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR. Anticancer Res, 12, 591–597.
Disis, M. L. & Cheever, M. A. (1997). HER-2/neu: a target for antigen-specific immunotherapy of human cancer. In Advances in Cancer Research, Vande Woude GF, Klein G (eds), pp. 343–371, Academic Press: Tokyo
Earp, H. S., Dawson, T. L., Li, X. & Yu, H. (1995). Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat, 35, 115–132.
Ethier, S. P., Kokeney, K. E., Ridings, J. W. & Dilts, C. A. (1996). erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line. Cancer Res, 56, 899–907.
Fendley, B. M., Winget, M., Hudziak, R. M., Lipari, M. T., Napier, M. A. & Ullrich, A. (1990). Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res, 50, 1550–1558.
Fujimoto-Ouchi, K., Tamura, S., Mori, K., Tanaka, Y. & Ishitsuka, H. (1995). Establishment and characterization of cachexia-inducing and -non-inducing clones of murine colon 26 carcinoma. Int J Cancer, 61, 522–528.
Graus-Porta, D., Beerli, R. R., Daly, J. M. & Hynes, N. E. (1997). Erb B-2, the preferred heterodimerization partner of all Erb B receptors, is a mediator of lateral signaling. EMBO J, 16, 1647–1655.
Karunagaran, D., Tzahar, E., Beerli, R. R., Chen, X., Graus-Porta, D., Ratzkin, B. J., Seger, R., Hynes, N. E. & Yarden, Y. (1996). Erb B-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J, 15, 254–264.
Kurebayashi, J., Kurosumi, M. & Sonoo, H. (1995). A new human breast cancer cell line, KPL-1 secretes tumour-associated antigens and grows rapidly in female athymic nude mice. Br J Cancer, 71, 845–853.
Kurebayashi, J., Kurosumi, M. & Sonoo, H. (1996). A new human breast cancer cell line, KPL-3C, secretes parathyroid hormone-related protein and produces tumours associated with microcalcifications in nude mice. Br J Cancer, 74, 200–207.
Lewis, G. D., Lofgren, J. A., McMurtrey, A. E., Nuijens, A., Fendly, B. M., Bauer, K. D. & Silwkowski, M. X. (1996). Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res, 56, 1457–1465.
Ohe, Y., Podack, E. R., Oslen, K. J., Miyahara, Y., Miura, K., Saito, H., Koishihara, Y., Ohsugi, Y., Ohira, T. & Nishio, K. (1993). Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumor growth rate but cause weight loss and shorten survival in syngenic mice. Br J Cancer, 67, 939–944.
Oka, M., Yamamoto, K., Takahashi, M., Hakozaki, M., Abe, T., Iizuka, N., Hazama, S., Hirazawa, K., Hayashi, H., Tangoku, A., Hirose, K., Ishihara, T. & Suzuki, T. (1996). Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal cell carcinoma. Cancer Res, 56, 2776–2780.
Plowman, G. D., Culouscou, J-M, Whitney, G. S., Green, J. M., Carlton, G. W., Foy, L., Neubauer, M. G. & Shoyab, M. (1993). Ligand-specific activation of HER4/p180erb4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA, 90, 1746–1750.
Prost, S., Le, M. G., Douc-Rasy, S., Ahomadegbe, J. C., Spielmann, M., Guerin, M. & Riou, G. (1994). Association of c-erbB-2 gene amplification with poor prognosis in non-inflammatory breast carcinomas but not in carcinomas of the inflammatory type. Int J Cancer, 58, 763–768.
Quian, X., LeVea, C. M., Freeman, J. K., Dougall, W. C. & Greene, M. I. (1994). Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation. Proc Natl Acad Sci USA, 91, 1500–1504.
Sainsbury, J. R. C., Fardon, J. C., Needham, G. K., Malcolm, A. J. & Harris, A. L. (1987). Epidermal-growth-factor receptor status as predictor of early recurrence and death from breast cancer. Lancet, 1, 1398–1402.
Shepard, H. M., Lewis, G. D., Sarup, J. C., Fendly, B. M., Maneval, D., Mordenti, J., Figari, I., Kotts, C. E., Palladino, M. A. Jr, Ullrich, A. & Slamon, D. (1991). Monoclonal antibody therapy of human breast cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol, 11, 117–127.
Strassmann, G., Fong, M., Kenney, J. S. & Jacob, C. O. (1992). Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest, 89, 1681–1684.
Takemura, M., Kiyoshima, M., Saito, K., Noma, A., Shinoda, J., Sato, M. & Kasai, C. (1996). Evaluation of interleukin-6 (IL-6) measurement by highly sensitive chemiluminescent enzyme immunoassay. Igaku-to-Yakugaku, 36, 1071–1076.
Tang, C. K., Perez, C., Grunt, T., Waibel, C., Cho, C. & Lupu, R. (1996). Involvement of heregulin-β2 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Res, 56, 3350–3358.
Travis, A., Pinder, S. E., Robertson, J. F. R., Bell, J. A., Wencyk, P., Gullick, W. J., Nicholson, R. I., Poller, D. N., Blamey, R. W., Elston, C. W. & Ellis, I. O. (1996). C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic factors. Br J Cancer, 74, 229–233.
Wada, T., Quian, X. & Greene, M. I. (1990). Intermolecular association of the p185neuprotein and EGF receptor modulates EGF receptor function. Cell, 61, 1339–1347.
Walker, R. A., Gullick, W. J. & Varley, J. M. (1989). An evaluation of immunoreactivity for c-erb B-2 protein as a marker of poor short-term prognosis in breast cancer. Br J Cancer, 60, 426–429.
Wright, C., Angus, B., Nicholson, S., Sainsbury, J., Cairns, J., Gullick, W. J., Kelly, P., Harris, A. L. & Wilson, H. C. H. (1989). Expression of c-erb B-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res, 49, 2087–2090.
Yamashita, J., Hideshima, T., Shirakusa, T. & Ogawa, M. (1996). Medroxyprogesterone acetate treatment reduces serum interleukin-6 levels in patients with metastatic breast carcinoma. Cancer, 78, 2346–2352.
Yasui, W., Sumiyoshi, H., Hata, J., Kameda, T., Ochiai, A., Ito, H. & Tahara, E. (1988). Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res, 48, 137–141.
Yasumoto, K., Mukaida, N., Harada, A., Kuno, K., Akiyama, M., Nakashima, E., Fujioka, N., Mai, M., Kasahara, T. & Fujimoto-Ouchi, K. (1995). Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice. Cancer Res, 55, 921–927.
Zhang, K., Sun, J., Liu, N., Wen, D., Chang, D., Thomason, A. & Yoshinaga, S. K. (1996). Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J Biol Chem, 271, 3884–3890.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Kurebayashi, J., Otsuki, T., Tang, C. et al. Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6. Br J Cancer 79, 707–717 (1999). https://doi.org/10.1038/sj.bjc.6690114
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690114
Keywords
This article is cited by
-
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results
Nature Communications (2024)
-
Protease-Activated Receptor 1 (PAR1) Expression Contributes to HPV-Associated Oropharyngeal Cancer Prognosis
Head and Neck Pathology (2023)
-
Ex vivo dual gene therapy using human adipocytes secreting anti-HER2 antibody on HER2-positive xenograft tumor models
Breast Cancer (2023)
-
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC
npj Breast Cancer (2022)
-
MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro
Scientific Reports (2021)